Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Intranasal Drug Delivery Devices Market Grown from 2024 to 2025?

There has been significant expansion in the market for intranasal drug delivery devices in recent times. The size of the market, which is expected to move from $60.27 billion in 2024 to a larger size of $65.59 billion by 2025, will witness a compound annual growth rate (CAGR) of 8.8%. Factors contributing to this growth during the historic period include the escalation in chronic respiratory conditions, patient inclinations and adherence, ease of self-medication, pediatric usages, growing market for allergic rhinitis treatments, and a broadening spectrum of applications.

What Growth Rate Is Anticipated for the Intranasal Drug Delivery Devices Market in the Coming Years?

Expectations are high for robust growth in the intranasal drug delivery devices market in the coming years. The market is projected to reach a towering value of $92.05 billion in 2029, with an impressive compound annual growth rate (CAGR) of 8.8%. This anticipated growth, during the forecast period, is believed to stem from factors such as the rise in the aging population, increasing global respiratory conditions, wider applications in neurological disorders, evolving trends in personalized medicine, initiatives towards preventive healthcare, and market expansion in emerging economies. Key trends projected to dominate the forecast period include progression in devising formulation technologies, emphasis on pediatric and geriatric applications, growth in self-administration devices and nasal powder inhalers, and the integration of biologics and peptides.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13463&type=smp

Who Are the Leading Companies in the Intranasal Drug Delivery Devices Market?

Major companies operating in the intranasal drug delivery devices market report are Johnson and Johnson Inc., Merck and Co.Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Teleflex Incorporated, Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group PLC, Douglas Pharmaceuticals Ltd., Avanir Pharmaceuticals, OptiNoset Inc., Flamel Technologies, Aegis Therapeutics LLC, Sonoma Pharmaceuticals, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, B.F. Ascher and Company Inc., ENT Technologies Pty. Ltd., Neurelis Inc., Generex Biotechnology Corporation

What Are the Key Drivers of the Intranasal Drug Delivery Devices Market?

Escalating rates of chronic illnesses are anticipated to fuel the expansion of the intranasal drug delivery devices market. Chronic diseases, those lasting for a year or longer requiring continual medical intervention, or impacting daily life activities can be managed using intranasal drug delivery devices. These devices offer a non-intrusive and efficacious method of medication administration, enabling treatment to be directly delivered to the affected area, offering convenience, ease of usage and fast assimilation. For example, the UK’s National Health Service announced in June 2024 that in 2023, a further 549,000 individuals in England were identified as being at risk of type 2 diabetes, raising the total population registered with a GP as non-diabetic hyperglycemia, or pre-diabetic, to 3,615,330. This denotes a considerable surge from 3,065,825 in 2022, signifying a near 20% increase. Consequently, the rising prevalence of chronic diseases is fueling the growth of the intranasal drug delivery devices market. The Intranasal Drug Delivery Devices Market is driven by a surge in demand for non-invasive drug conveyance. The growing demand for non-invasive methodologies of drug administration is projected to drive the growth of the intranasal drug delivery device market. Non-invasive drug delivery implies pharmaceutical administration without the need for skin penetration or mucous membrane incision. Intranasal drug delivery devices are employed for non-invasive drug delivery, allowing for easy and effective medication administration via the nose. These devices utilize the rich vascularization and fast absorption of the nose, thereby enhancing drug bioavailability and patient compliance while decreasing the necessity for invasive procedures. In August 2023, The US-based Aesthetic Society reported a significant rise in non-surgical procedures with body contouring, skin treatment, toxins, and micro needling showing growth rates of 31%, 26%, 24%, and 23%, respectively in 2022. Thus, the escalating demand for non-invasive drug delivery forms is propelling the growth of the intranasal drug delivery device market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13463&type=smp

What Are the Key Market Segments in the Intranasal Drug Delivery Devices Industry?

The intranasal drug delivery devices market covered in this report is segmented –

1) By Product: Powder Delivery Device, Liquid Delivery Device, Pressurized Metered-Dose Inhalers, Other Products

2) By Dosage: Unit-Dose, Multi-Dose

3) By Application: Chronic Obstructive Pulmonary Disease (COPD), Rhinitis, Cystic Fibrosis, Nasal Congestion, Asthma, Other Applications

4) By End User: Hospitals, Clinics, Homecare, Other End Users

Subsegments:

1) By Powder Delivery Device: Single-Dose Powder Device, Multi-Dose Powder Device

2) By Liquid Delivery Device: Single-Dose Liquid Device, Multi-Dose Liquid Device

3) By Pressurized Metered-Dose Inhalers (pMDIs): Breath-Actuated PMDIs, Conventional pMDIs

4) By Other Products: Gel Delivery Device, Nebulizers, Nasal Sprays

What Are the Latest Trends in the Intranasal Drug Delivery Devices Market?

Leading pharmaceutical firms in the nasal drug delivery technology market are innovating new and enhanced products to offer their clients alternative drug administration techniques and maintain their market standing. For example, in January 2023, AptarGroup, Inc., a pharmaceutical and drug delivery corporation based in the US, introduced the first-ever recyclable, metal-free, multidose nasal spray, APF Futurity, for the delivery of nasal saline and similar over-the-counter (OTC) formulations. APF Futurity is crafted from polyolefin materials, with no inclusion of metal parts or elements that could disrupt recycling. This minimizes the necessity for separation in the recycling process, thereby enhancing the quality of recycled materials. The distinct aspect of this product is its design promoting recyclability; it’s recognized as a highly recyclable nasal spray pump with a Class AA certification from cyclos-HTP for European recycling streams.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intranasal-drug-delivery-devices-global-market-report

What Are the Key Regional Markets in the Intranasal Drug Delivery Devices Industry?

North America was the largest region in the intranasal drug delivery devices market in 2024. The regions covered in the intranasal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13463

This Report Delivers Insight On:

1. How big is the intranasal drug delivery devices market, and how is it changing globally?

2. Who are the major companies in the intranasal drug delivery devices market, and how are they performing?

3. What are the key opportunities and risks in the intranasal drug delivery devices market right now?

4. Which products or customer segments are growing the most in the intranasal drug delivery devices market?

5. What factors are helping or slowing down the growth of the intranasal drug delivery devices market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model